Background Early identification of individuals with mild cognitive impairment (MCI) and
Alzheimer's disease (AD) is a clinical and research imperative. Use of diagnostic codes for …

Background: Alzheimer's disease (AD) and mild cognitive impairment (MCI) have negative
quality of life (QoL) and economic impacts on patients and their caregivers and may …

Objectives Neuropsychiatric symptoms (NPS) increase risk of developing dementia and are
linked to various neurodegenerative conditions, including mild cognitive impairment (MCI …

Background: Diagnostic codes can be instrumental for case identification in Alzheimer's
disease (AD) research; however, this method has known limitations and cannot distinguish …

Purpose: We aimed to examine the clinical characteristics of US veterans who underwent
neurocognitive test score-based assessments of Alzheimer disease (AD) stage in the …

Background Updated prevalence estimates along the continuum of Alzheimer's disease
(AD) can foster a more nuanced and effective approach to managing AD within the current …

Introduction The benefits of early detection of Alzheimer's disease (AD) have become
increasingly recognized. Veterans with mental health conditions (MHCs) may be less likely …

Background: Alzheimer's disease (AD) and related dementias are progressive neurological
disorders with stage-specific clinical features and challenges. An important knowledge gap …

Abstract The Centers for Medicare and Medicaid Services (CMS) has recently issued a
national coverage determination for US Food and Drug Administration (FDA)-approved anti …